Ontology highlight
ABSTRACT: Purpose of review
We review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development.Recent findings
Favipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effe
SUBMITTER: Hayden FG
PROVIDER: S-EPMC6416007 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature